（rs2279744）多态性与表达变化与斯洛伐克人群前列腺癌风险的关联。

Association of (rs2279744) Polymorphism and Expression Changes With Risk of Prostate Cancer in the Slovak Population.

机构信息

Department of Medical Biochemistry, Comenius University in Bratislava, Jessenius Faculty of Medicine, Martin, Slovak Republic

Department of Medical Biochemistry, Comenius University in Bratislava, Jessenius Faculty of Medicine, Martin, Slovak Republic.

出版信息

Anticancer Res. 2020 Nov;40(11):6257-6264. doi: 10.21873/anticanres.14646.

DOI:10.21873/anticanres.14646

PMID:33109563

Abstract

BACKGROUND/AIM: The aim of this study was to evaluate the relationship between MDM2 T309G polymorphism and prostate cancer risk in the Slovak population and the association of this polymorphism with MDM2 expression and clinicopathological features.

MATERIALS AND METHODS

The MDM2 T309G polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis in 506 prostate cancer patients and 592 controls. Quantitative real-time (RT)-PCR and western blot analysis were applied to examine MDM2 expression in 47 prostate cancer tissues and 43 benign prostatic hyperplasia (BPH) tissues.

RESULTS

A decreased risk of prostate cancer in men carrying the GG genotype in comparison with the TT genotype was found. A decrease in the relative MDM2 mRNA and protein levels was found in prostate cancer tissues among patients with the MDM2 GG genotype.

CONCLUSION

There is a potentially protective effect of the MDM2 GG genotype on the risk of prostate cancer in the Slovak male population.

摘要

背景/目的：本研究旨在评估斯洛伐克人群中 MDM2 T309G 多态性与前列腺癌风险之间的关系，并探讨该多态性与 MDM2 表达和临床病理特征的关联。

材料和方法

采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）分析方法，在 506 例前列腺癌患者和 592 例对照中检测 MDM2 T309G 多态性。应用实时定量（RT）-PCR 和 Western blot 分析检测 47 例前列腺癌组织和 43 例良性前列腺增生（BPH）组织中的 MDM2 表达。